Mayo Clinic expands AI-driven biomarker diagnostics partnership

The investment will accelerate the delivery of tests addressing kidney function and cardiac risk expected to gain U.S. Food and Drug Administration 510(k) approval early next year, according to the announcement.
WHY IT MATTERS
Using algorithms to analyze multiple biomarkers to measure disease…

From: www.healthcareitnews.com – Read more